{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001046","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.347082+00:00","generated_at":"2026-06-20T10:55:37.166544+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Finch Therapeutics ends Phase 3 CP101 trial, cuts 95% of staff to focus on IP monetization","bullets":["Discontinued PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection; cites capital outlook, slow enrollment, unauthorized IP use.","Workforce reduced by 77 employees (~95% of employee base); most roles end Feb 2023, some continued into May 2023.","Expected restructuring costs of approximately $4.1 million from severance, outplacement and related expenses; charges recorded in H1 2023.","Company holds over 70 issued U.S. and foreign patents microbiome therapeutics and will seek to realize value from its IP estate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001046","json":"https://secwatch.observer/filing/0000950170-23-001046.json","markdown":"https://secwatch.observer/filing/0000950170-23-001046.md","text":"https://secwatch.observer/filing/0000950170-23-001046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023001046/0000950170-23-001046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023001046/fnch-20230123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T10:55:37.166544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42b85c0f8632cb9133aa21b2a81f6176fa37a246","claim":"Finch Therapeutics Group, Inc. announced a restructuring with charges of approximately $4.1 million (reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee b).","evidence_excerpt":"On January 24, 2023, Finch Therapeutics Group, Inc. (the “Company”) announced decisions to discontinue its Phase 3 clinical trial of CP101 in recurrent C. difficile infection and to focus on realizing the value of its intellectual property estate and other assets. In connection with these decisions, on January 23, 2023, the Company’s board of directors approved certain expense reduction measures, including a reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee base (the “Restructuring”). The Company initiated the Restructuring on January 24, 2023, with the majority of impacted positions ending in February 2023 and a small portion of positions maintained into May 2023. As a result of the Restructuring, the Company estimates that it will incur approximately $4.1 million in costs resulting from cash expenditures consisting of one-time severance payments, outplacement services and related expenses.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023001046/0000950170-23-001046-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.1 million"},{"label":"Headcount","value":"reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee b"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}